Work

Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps8655

Authors: David Ross Camidge, Nicolas Girard, Shun Lu, Shirish M. Gadgeel, Kristof Cuppens, Se-Hoon Lee, Hidehito Horinouchi, Tae Min Kim, Angelo Delmonte, Elvire Pons-Tostivint, Robert M. Jotte, Nivedita Aanur, Han Coburn, Qi Jiang, Theodore S. Jennaro, Tony Navas, Yan Li, Jonathan W. Goldman

Institutions: University of Colorado Cancer Center, Institut Curie, Shanghai Jiao Tong University, Shanghai Chest Hospital, Henry Ford Health, Henry Ford Hospital, Jessa Hospital, Samsung Medical Center, National Cancer Center Hospital, Seoul National University Hospital, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Centre Hospitalier Universitaire de Nantes, Nantes Université, Rocky Mountain Cancer Centers, AbbVie (United States), University of California, Los Angeles

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: AbbVie

OpenAlex ID: W4410804524

FWCI: 0.591

Cites:

Cited by: 1

Related to: 10